Not actual patients. LYNAVOY is not approved for use in children.
LYNAVOY delivers clinically meaningful itch
and sleep
improvements1,6
Clinically meaningful itch relief over 24 weeks1,6
Primary Endpoint: Change from baseline in Monthly Itch Score* over 24 weeks1
Clinically meaningful improvement in itch was defined by the FDA as a ≥2.5- to 4-point
reduction from baseline over
24 weeks6
- Statistically significant improvement from baseline vs placebo over 24 weeks
-
LS mean difference vs placebo:
−0.7 (95% CI: −1.15 to −0.28); P=0.001
*The Monthly Itch Score was computed as the worst (highest) Weekly Itch Score within a 4-week period.1
CI=confidence interval; LS=least-squares.
Rapid itch relief: Nearly
2-point itch improvement at Week 21,7
Change from baseline in monthly itch score over 2 weeks
LYNAVOY improved itch by
66% more than
placebo at
Week 21†
†−0.7 LS mean difference, a 66% greater improvement for itch score compared to placebo.
LYNAVOY is the FIRST AND ONLY cholestatic pruritus in PBC treatment that achieved a
statistically significant reduction in
itch at Week 21,2
Patients’ itch improved from severe to mild1,7
Mean monthly itch scores at baseline and Week 24 with LYNAVOY‡
On average, patients on LYNAVOY improved their itch scores from severe (>7) at baseline to mild (<4) at 24 weeks1,7†
‡Monthly itch scores reduced from 7.3 at baseline to 4.5 at Week 24 with placebo.1,7
Not an actual patient.
Help keep itch from disrupting their sleep1
Clinically meaningful and significant improvement in pruritus-related sleep interference vs placebo over 24 weeks1,6
Key secondary endpoint: Change from baseline in monthly sleep1
-2.8 -point
mean change from baseline in pruritus-related sleep score at Week 24 with LYNAVOY
Mean difference vs placebo: −0.53 (95% CI: −0.98 to −0.07); P=0.024
LYNAVOY is the only treatment proven to reduce pruritus-related sleep interference1
Changes in itch severity were observed following treatment switching in an exploratory analysis7
Patients who switched from LYNAVOY to placebo showed increased itch severity, while those who switched from placebo to LYNAVOY showed decreased itch severity7
Patients previously treated with LYNAVOY who switched to placebo at Week 24 experienced an increase in mean itch severity within 2 weeks7
Part B was an 8-week, blinded, randomized, withdrawal period. Change in weekly itch score from Week 24 to Week 32 was an exploratory endpoint evaluating changes in pruritus following treatment continuation or withdrawal.7
Changes in itch severity observed during continuous LYNAVOY treatment8,9
Based on an interim analysis of data collected over 1 year from an ongoing, open-label study9
Eligible patients from a phase 3 GLISTEN and phase 2b GLIMMER trials could enroll in LLSAT, in which all patients received continuous oral LYNAVOY at 40 mg twice daily9
Change in WI-NRS weekly scores for patients receiving LYNAVOY in
GLISTEN Part A and who entered LLSAT8,9
§Based on a descriptive analysis of monthly WI-NRS scores in patients receiving 52 weeks of continuous linerixibat treatment (n=37). Mean change from baseline: −4.87 points. Weeks that start with “L” are the LLSAT weeks. Interim efficacy data (data cutoff: July 31, 2025). As this is an open-label, noncomparator study, no statistical test for comparison was performed. All analyses were descriptive with no inferential testing performed. LLSAT was a long-term study with frequency and severity of adverse events as the primary endpoint; maintenance of efficacy was assessed as a secondary endpoint.8,9
A study designed to measure itch relief for patients with cholestatic pruritus in PBC1,7
GLISTEN was a phase 3, randomized, double-blind, placebo-controlled study in cholestatic pruritus in PBC1,7,10
53% of patients had ALP <1.67.1
Patients were randomized to LYNAVOY or placebo in Part A, which evaluated the efficacy and safety of LYNAVOY over 24 weeks. In Part B, patients either continued treatment or transitioned to the alternate treatment group to evaluate changes in itch severity following continuation or withdrawal of treatment.1,7
Key efficacy endpoints:
- Primary endpoint: Change from baseline in Monthly Itch Score over 24 weeks1
- Secondary endpoints: Change from baseline in Weekly Itch Score at Week 2, and change from baseline in Monthly Sleep Score over 24 weeks1,7
Across the LYNAVOY and placebo groups, 97% of patients in GLISTEN were receiving UDCA, and 47% were receiving concomitant antipruritic drugs1,7
Itch assessment: Patients rated their worst itch severity each morning and evening using the 11-point WI-NRS (0=no itch; 10=worst imaginable itch).
- Worst Daily Itch Score: Highest of the two scores (morning or evening) recorded in
a day - Weekly Itch Score: Average of the Worst Daily Itch Scores over
7 days - Monthly Itch Score: Worst (highest) Weekly Itch Score within a 4-week period
Sleep assessment: Patients rated pruritus-related sleep
interference each morning
using the 11-point Sleep Interference
NRS (0=no interference; 10=complete
interference).
- Weekly Sleep Score: Average of the Daily Sleep Scores recorded over the 7 days in a
week - Monthly Sleep Score: The worst (highest) Weekly Sleep Score within a 4-week period
ALP=alkaline phosphatase; CI=confidence interval; GLISTEN = Global Linerixibat Itch STudy of Efficacy and safety iN primary biliary cholangitis; LLSAT=Linerixibat Long-term Safety and Tolerability Study; LS=least-squares; NRS=Numeric Rating Scale; SE=standard error; UDCA=ursodeoxycholic acid; WI-NRS=Worst Itch Numeric Rating Scale.